Sequential use of sorafenib and sunitinib in advanced renal‐cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient casesCamillo Porta, Emilio Bajetta, Giuseppe Procopio et al.|British Journal of Urology|2011Cited by 87
Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancerSerena Di Cosimo, Francesco Cognetti, Andrea Alimonti et al.|Annals of Oncology|2004Cited by 64
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): Is a clinical benefit still achievable?Paolo Carlini, Francesco Cognetti, Antonio Frassoldati et al.|Annals of Oncology|2001Cited by 43
Does Granulocyte Colony-Stimulating Factor Worsen Anemia in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?Paola Papaldo, Francesco Cognetti, G. Ferretti et al.|Journal of Clinical Oncology|2006Cited by 42
Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trialsG. Ferretti, Paolo Carlini, Diana Giannarelli et al.|British Journal of Cancer|2006Cited by 38